Crizotinib, an inhibitor of anaplastic lymphoma kinase (ALK) and c-ros oncogene 1 (ROS1), is approved for the treatment of patients with ALK-positive (ALK+) or ROS1-positive (ROS1+) advanced non-smallcell lung cancer (NSCLC). The ALK rearrangements are also implicated in anaplastic large-cell lymphoma (ALCL), which is characterized by
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.